Status:
COMPLETED
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
Lead Sponsor:
ORA, Inc.
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
Eligibility Criteria
Inclusion
- be at least 18 years old
- be willing and able to avoid all disallowed medications and contact lenses
- must have a pregnancy test if of childbearing potential
- must be able to read an eye chart from 10 feet away
Exclusion
- must not have any allergies to the study medications
- must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
- must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial
Key Trial Info
Start Date :
October 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03320434
Start Date
October 13 2017
End Date
February 18 2018
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Andover Eye Associates
Andover, Massachusetts, United States, 01810